Microcap Ledger Sagimet Biosciences Inc. $SGMT
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Foster City, CA
- Fiscal year end
- December 31
- Shares outstanding
- 30,674,855 [10-Q 2024-11-14]
What the company doesAI summary of filing
Sagimet Biosciences is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors for diseases caused by excess palmitate production. The company's lead candidate, denifanstat, is an oral once-daily pill in development for metabolic dysfunction-associated steatohepatitis (MASH), acne, and select cancers; denifanstat met primary and secondary endpoints in a Phase 2b trial for MASH with moderate to advanced fibrosis and received FDA Breakthrough Therapy designation in October 2024. The company's second candidate, TVB-3567, is a selective FASN inhibitor in Phase 1 development for acne. Sagimet is pre-revenue and generates no current product sales, instead funding operations through the development of its drug candidates toward regulatory approval. [10-K 2026-03-11]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$24.60M | −$19.71M | $165.90M | [10-Q 2026-08-11] |
| FY ended Dec 2025 | — | −$51.04M | −$45.65M | $35.02M | [10-K 2026-03-11] |
| FY ended Dec 2024 | — | −$45.57M | −$42.44M | $75.84M | [10-K 2026-03-11] |
- Quarterly cash burn
- −$9.86M
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2023-11-09 | 21,375,402 | [10-Q 2023-11-13] |
| 2024-05-10 | 30,393,397 | [10-Q 2024-05-15] |
| 2024-08-09 | 30,674,855 | [10-Q 2024-08-14] |
| 2024-11-08 | 30,674,855 | [10-Q 2024-11-14] |
- Shelf registration
- S-3 filed 2024-08-15; declared effective 2024-08-26 [S-3 2024-08-15]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-14 | Kemble George | exercise | 326,618 | $6.36 | [4 2026-08-17] |
| 2026-08-14 | Kemble George | exercise | 24,369 | $6.36 | [4 2026-08-17] |
| 2026-08-14 | Kemble George | sell | 350,987 | $10.23 | [4 2026-08-17] |
| 2026-08-11 | Kemble George | exercise | 9,751 | $6.36 | [4 2026-08-12] |
| 2026-08-11 | Kemble George | exercise | 10,455 | $6.36 | [4 2026-08-12] |
| 2026-08-11 | Kemble George | sell | 20,206 | $9.95 | [4 2026-08-12] |
| 2026-07-20 | Happel David | sell | 64,051 | $7.76 | [4 2026-07-22] |
| 2026-07-20 | Rozek Elizabeth | sell | 10,545 | $7.76 | [4 2026-07-22] |
| 2026-07-20 | Kemble George | sell | 18,844 | $7.46 | [4 2026-07-22] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-07 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-10-01 | 8-K | Material agreement entered |
| 2026-10-01 | 424B5 | Prospectus or prospectus supplement |
| 2026-09-30 | 8-K | Regulation FD disclosure; Other events |
| 2026-09-30 | 424B3 | Prospectus or prospectus supplement |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 8-K | Other events |
| 2026-08-11 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-08-11 | 10-Q | Quarterly report |
| 2026-07-30 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-07-21 | 8-K | Regulation FD disclosure |
| 2026-06-12 | 8-K | Director or officer change; Shareholder vote results |
Alerts for $SGMT
Email me when Sagimet Biosciences Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.